Discuss your needs with Mewburn Ellis
Mewburn Ellis is well placed to assist clients with all aspects of ADC and bsAb IP.
Mewburn Ellis has a long history of working with leaders in the field of monoclonal antibodies and continues to be a go-to IP firm in this space. Find out more here.
With extensive experience in bispecific and multispecific formats we have protected platform technologies as well as many individual products including Lunsumio® and Vabysmo®.
We also have specialists in antibody-drug conjugates (ADCs) in both our life sciences and chemistry teams, who are familiar with the latest research concerning the payload, linker and antibody elements, as well as the complex interplay between these parts. Our ADC experience spans the full drug development cycle, having guided the development of the portfolio behind Zynlonta® right from the first chemistry patents for the payload through to FDA approval of the ADC. Other notable work in the targeted drug conjugate space work includes high-profile ADCs such Kadcyla® and Lumoxti®, as well as developments in the field of antibiotic-antibody drug conjugates.
Our Patent Oppositions and Appeals experts have an
enviable success rate and have a long track record of success in oppositions in the ADC and bsAb space at the EPO, both offensive (opposing the patents of other parties) and defensive (defending the patents of our clients). Several of our attorneys have also been involved litigating antibody patents in the European courts, for example, pan-European litigation on anti-PD-1 antibodies. Our experience of seeing patents throughout their full life-span feeds back to strong and robust patent drafting.
We have additional expertise in machine learning, and we can advise on how patents relating to machine learning may be used by ADC and bispecific companies as part of a wider commercial strategy.
We also have a speciality pharma team, who advise on supplementary protection certificates (SPCs) and patent term extensions, as well as regulatory and data exclusivity and patent listing, all vital components in effective IP protection in the pharmaceutical sector. We can help companies to identify opportunities for patents to follow-on inventions, e.g., arising from clinical trial data.
We operate as one team, so that we can bring our depth and breadth of expertise across all of these areas to benefit our clients.
For more help and advice please do get in touch. We’d love to hear from you!
Our specialists
© 2025 Mewburn Ellis
